GrayMatters Health News
8 articles
growth-positive
Israeli startup GrayMatters treats PTSD with avatars
Israeli company GrayMatters, which develops innovative treatments for post-traumatic stress disorder (PTSD), has received approval from the US FDA and Israels Ministry of Health to market its technology. The company uses AI software and an EEG headset device to read biomarker activity in the amygdala, the part of the brain which is overactive in people suffering from PTSD. The treatment is administered during 15 visits each lasting 30 minutes, in which the patients see avatars in front of them that they have to move. The company has raised $20 million to date and has begun initial sales in the US.
CustomersInvestmentPartners
Growth-Positive
GrayMatters Health Receives Investment from European Innovation Council (EIC) Fund
GrayMatters Health (GMH), a developer of digital self-neuromodulation therapies for mental disorders, has received an investment from the European Innovation Council (EIC) Fund. This follows a €2.5M grant awarded to GMH by the EIC in September 2022. The funds will be used for the continued development of GMHs flagship product, Prism for PTSD, a non-invasive digital therapy for post-traumatic stress disorder (PTSD), and for a large-scale study in the EU. The EIC Funds investment was advised by the European Investment Bank (EIB).
InvestmentExpand
GrayMatters Health Awarded €2.5M in Funding from European Innovation Council
growth-positive
GrayMatters Health Closes $10M Round A Funding and Partnership in Japan
GrayMatters Health (GMH), a developer of digital self-neuromodulation therapeutics for mental disorders, has raised $10 million in a Series A funding round. The round was led by Otsuka Medical Devices Co., Ltd. (OMD), and included participation from Joy Ventures, J-Ventures, J-Impact, Marius Nacht, and Joyance Ventures. GMH will use the funds to complete its clinical investigation, obtain regulatory clearance, and launch Prism for PTSD in the United States. Prism is a non-invasive adjunct digital therapeutic that uses machine learning technology to create an Electrical-Finger-Print (EFP) of brain-mechanism-specific biomarkers for the treatment of mental disorders.
Investment
growth-positive
McLean Hospital and GrayMatters Health Awarded a BIRD Foundation Grant to Develop a Digital Therapy for Major Depression Disorder with Anhedonia Symptoms
Digital therapeutics start-up GrayMatters Health and McLean Hospital have been awarded a grant by the BIRD Israel-U.S. Binational Industrial Research and Development Foundation. The grant will fund the development of a novel solution for the therapy of Major Depression Disorder (MDD) based on GrayMatters patented fMRI-to-EEG machine-learning platform, Prism. The treatment aims to help individuals with MDD who are unable to feel pleasure learn how to control and modulate their reward system. The project will also allow GrayMatters to expand its indications from PTSD to depression.
PartnersInvestment
growth-positive
https://www.jpost.com/jpost-tech/bird-to-invest-6m-in-joint-us-israel-innovation-projects-674225
The BIRD Foundation has announced collaborations between US and Israeli companies for joint product development in various technological sectors. The collaborations include Cyberint Technologies and Secure Systems Innovation Corporation, YonaLink and Trialjectory, GrayMatters Health and McLean Hospital Corporation, Over-Sat and MIL-SAT, Sensifree and the Cleveland Clinic, and Skillreal and Siemens DI. The projects will receive grants from BIRD and private sector funding, bringing the total value of all projects to $13m. To date, BIRD’s total investment in joint projects is over $370m.
PartnersInvestment
growth-positive
GrayMatters Health Wins Awards for its Innovative Technology for the Treatment of Mental Disorders
GrayMatters Health, a digital therapeutics start-up, has won a series of international awards for its innovative medical technology for treating mental disorders such as PTSD. The company was one of the top eight to be awarded the 2021 Nature Spinoff Prize, sponsored by Nature and the Merck Group. It was also selected by the HITLAB Breakthrough Alliance (BTA), which will allow GrayMatters Health to work with HITLAB to verify its solution with additional providers and US-based health insurance companies. The company also won First Place in the 2021 SelectUSA Investor Summit Medtech track.
CustomersPartners
growth-positive
Beyond the Pill: a startup reimagines mental health
GrayMatters Health, an Israel-based startup, is developing digital therapeutics for mental disorders. The companys product, Prism for PTSD, uses a machine learning computational model to reproduce the fMRI signal of the amygdala using EEG in real time. This allows patients to learn how to downregulate their amygdala activity, which can lead to clinical improvement in mental disorders such as PTSD. The company aims to work alongside traditional methods to improve clinical outcomes, rather than replace them. GrayMatters Health is planning to expand its portfolio beyond PTSD and venture into the German market.
CustomersExpand
